NEW YORK (GenomeWeb) – OncoCyte announced on Wednesday that it has closed a $10 million private placement with two unnamed existing investors.

According to OncoCyte, the investors agreed to buy 7,936,508 shares of the company's common stock at $1.26 per share. OncoCyte said that it has already received $8 million from the stock sale and that one investor has committed to purchasing $2 million worth of additional shares before April 30.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.